Cite
HARVARD Citation
Lim, J. et al. (2019). Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. Future oncology. pp. 1493-1504. [Online].